Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

被引：2
|
作者：
Vij, Ravi [1 ]
Savona, Michael [2 ]
Siegel, David S. [3 ]
Kaufman, Jonathan L. [4 ]
Badros, Ashraf [5 ]
Ghobrial, Irene M. [6 ]
Paner, Agne [7 ]
Jagannath, Sundar [8 ]
Jakubowiak, Andrzej [9 ]
Mikhael, Joseph R. [10 ]
Kapoor, Prashant [11 ]
Neuman, Linda L. [12 ]
Lee, Ju RueyJiuan [13 ]
Berdeja, Jesus G. [14 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[3] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Univ Maryland, Baltimore, MD 21201 USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[8] Mt Sinai Hosp, New York, NY 10029 USA
[9] Univ Chicago Med, Chicago, IL USA
[10] Mayo Clin Arizona, Scottsdale, AZ USA
[11] Mayo Clin, Rochester, MN USA
[12] Onyx Pharmaceut Inc, Redwood City, CA USA
[13] Onyx Pharmaceut Inc, San Francisco, CA USA
[14] Sarah Cannon Res Inst, Nashville, TN USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB (OPZ) IN PATIENTS (PTS) WITH HEMATOLOGIC MALIGNANCIES, INCLUDING MULTIPLE MYELOMA (MM)
    Vij, R.
    Savona, M.
    Siegel, D.
    Kaufman, J. L.
    Badros, A.
    Ghobrial, I.
    Paner, A.
    Jagannath, S.
    Jakubowiak, A.
    Mikhael, J.
    Kapoor, P.
    Neuman, L.
    Obreja, M.
    Berdeja, J.
    HAEMATOLOGICA, 2015, 100 : 251 - 251
  • [2] Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Waldenstrom Macroglobulinemia (WM)
    Siegel, David S.
    Kaufman, Jonathan L.
    Raje, Noopur S.
    Mikhael, Joseph R.
    Kapoor, Prashant
    Treon, Steven P.
    Castillo, Jorge J.
    Neuman, Linda L.
    Lee, Ju RueyJiuan
    Ghobrial, Irene
    BLOOD, 2014, 124 (21)
  • [3] Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies
    Ghobrial, Irene M.
    Savona, Michael R.
    Vij, Ravi
    Siegel, David S.
    Badros, Ashraf
    Kaufman, Jonathan L.
    Raje, Noopur
    Jakubowiak, Andrzej
    Obreja, Mihaela
    Berdeja, Jesus G.
    BLOOD, 2016, 128 (22)
  • [4] UPDATED RESULTS FROM A MULTICENTER, OPEN-LABEL, DOSE-ESCALATION PHASE 1B/2 STUDY OF SINGLE-AGENT OPROZOMIB IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, INCLUDING WALDENSTROM MACROGLOBULINEMIA
    Siegel, D.
    Kaufman, J. L.
    Raje, N.
    Mikhael, J.
    Kapoor, P.
    Treon, S.
    Castillo, J.
    Neuman, L.
    Obreja, M.
    Ghobrial, I.
    HAEMATOLOGICA, 2015, 100 : 461 - 461
  • [5] OPROZOMIB (OPZ) AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM DOSE ESCALATION IN A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY
    Hari, P.
    Shain, K. H.
    Voorhees, P.
    Gabrail, N.
    Abidi, M.
    Zonder, J.
    Boccia, R.
    Richardson, P. G.
    Neuman, L.
    Wong, H.
    Dixon, S.
    Prada, C. P.
    HAEMATOLOGICA, 2015, 100 : 254 - 255
  • [6] Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study
    Hari, Parameswaran N.
    Shain, Kenneth H.
    Voorhees, Peter M.
    Gabrail, Nashat
    Abidi, Muneer H.
    Zonder, Jeffrey
    Boccia, Ralph V.
    Richardson, Paul G.
    Neuman, Linda L.
    Dixon, Sandra J.
    Prada, Claudia Paba
    BLOOD, 2014, 124 (21)
  • [7] Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hari, Parameswaran
    Paba-Prada, Claudia E.
    Voorhees, Peter M.
    Frye, John
    Chang, Yu-Lin
    Moreau, Philippe
    Zonder, Jeffrey
    Boccia, Ralph
    Shain, Kenneth H.
    LEUKEMIA RESEARCH, 2019, 83
  • [8] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
    Mateos, M., V
    Chari, A.
    Nah, H.
    Lokhorst, H.
    Kaufman, J. L.
    Moreau, P.
    Oriol, A.
    Plesner, T.
    Benboubker, L.
    Hellemans, P.
    Masterson, T.
    Clemens, P. L.
    Liu, K.
    San-Miguel, J.
    Usmani, S. Z.
    HAEMATOLOGICA, 2018, 103 : 32 - 33
  • [9] Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
    Usmani, Saad Z.
    Nahi, Hareth
    Mateos, Maria-Victoria
    Lokhorst, Henk M.
    Chari, Ajai
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    Liu, Kevin
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
  • [10] Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study
    Chari, Ajai
    Nahi, Hareth
    Mateos, Maria-Victoria
    Lokhorst, Henk M.
    Kaufman, Jonathan L.
    Moreau, Philippe
    Oriol, Albert
    Plesner, Torben
    Benboubker, Lotfi
    Hellemans, Peter
    Masterson, Tara
    Clemens, Pamela L.
    Liu, Kevin
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    BLOOD, 2017, 130
12345